CDKN2A R87P

CI-VAR-00003920Explore in graph →NP_000068.1:p.Arg87ProNM_000077.4:c.260G>CClinVar 236984 CIViC 3376 rs878853647

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Unmapped disease1unmapped disease
CDKN2A R87P	(functional)	Functional	D	Supports Loss Of Function	4	submitted	EID9411 Cancer-associated mutations in p16 (CDKN2A) were assessed for their ability to bind cyclin-dependent kinases, inhibit kinase activity, and induce cell-cycle arrest in G1 phase. R87P caused a loss of b… (full text at CIViC) PMID 10491434 · Yarbrough et al., 1999 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
236984	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Familial melanoma; Hereditary cancer-predisposing syndrome; Melanoma, cutaneous malignant, susceptibility to, 2; Melanoma and neural system tumor syndrome	germline	5	Jan 21, 2025	clinvar